Haemonetics Dividend

Dividend criteria checks 0/6

Haemonetics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield1.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$2.49
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28
Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09
Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Sep 07
We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if HAE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HAE's dividend payments have been increasing.


Dividend Yield vs Market

Haemonetics Dividend Yield vs Market
How does HAE dividend yield compare to the market?
SegmentDividend Yield
Company (HAE)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (HAE)0%

Notable Dividend: Unable to evaluate HAE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HAE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate HAE's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HAE has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.